First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Gozde Colak, PhD
339-707-5855
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Florida Cancer Specialists
Sarasota, Florida, United States
Judy Wang, MDRecruiting - Karmanos Cancer Institute
Detroit, Michigan, United States
Wasif Saif, MDRecruiting - Scri Oncology Partners
Nashville, Tennessee, United States
Deepak Bhamidipati, MDRecruiting - Md Anderson Cancer Center
Houston, Texas, United States
Timothy Yap, MD, PhDRecruiting - Next Oncology
San Antonio, Texas, United States
Ildefonso Ismael Rodriguez Rivera, MDRecruiting - Next Virginia
Fairfax, Virginia, United States
Alexander Spira, MD, PhD, FACPRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 21 Mar 2025
- Primary completion
- 30 Apr 2027
- Completion
- 30 Aug 2027
- Last update posted
- 7 Jul 2026
- Registered enrollment
- 90
- Registry id
- NCT06799065
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.